MediWound Ltd (NAS:MDWD)

Q2 2026 Mediwound Ltd Earnings Call Transcript

Aug 13, 2026 / 12:30 PM GMT

Release Date Price: $13.53 (-2.73%)

Transcript

Key Points

Positve

MediWound Ltd (MDWD) reaffirmed its full-year 2026 revenue guidance of $24 million to $26 million, with a revenue profile weighted toward the second half of the year.
The EscharEx Phase 3 VALUE trial is on track, with interim sample size reassessment and enrollment completion expected by the end of Q1 2027, and the company is close to having all ~40 sites recruiting.
Updated U.S. market assessment for EscharEx, now including pressure ulcers, estimates annual peak sales at $1.05 billion, expanding the commercial opportunity.
NexoBrid achieved its strongest quarter since launch, with record quarterly revenue, hospital unit sales, and ordering centers, and approximately 80 burn centers have ordered the product.
The new master service agreement with VeriCell, following the BARDA contract, is expected to generate revenue in H2 2026, and the company is advancing a room-temperature stable formulation funded by the Department of War.
The company has a broad collaboration network with major advanced wound care companies, positioning EscharEx as a leading non-surgical debridement therapy.

Negative

Q2 2026 revenue declined to $3.1 million from $5.7 million in Q2 2025, primarily due to the timing of BARDA-funded development revenue.
Gross margin fell to 10.9% from 23.5% in the prior year period, impacted by a one-time facility scale-up cost.
Operating loss widened to $9.5 million in Q2 2026 from $5.7 million in Q2 2025, driven by increased R&D investment in the VALUE trial.
Cash burn was $20 million in the first half of 2026, reducing cash to $36 million from $54 million at year-end 2025.
The expanded manufacturing facility for NexoBrid is delayed, with commercial supply now expected in the second half of 2027, subject to regulatory approval.
The company faces potential competition from Smith & Nephew's second-generation Santyl product, though it is not yet in clinical development for chronic wounds.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

MDWD.OQ - Mediwound Ltd
Q2 2026 Mediwound Ltd Earnings Call
Aug 13, 2026 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day and welcome to the MediWoon Second Quarter 2026 Earnings Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by zero.

After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on a touchtone phone.

To withdraw your question, please press star then two. Please note this event is being recorded.

I would now like to turn the conference over to Gaia Shamus from Lifestyle Advisors. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
-----------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.